Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | TYR | P14679 | 1/20 | 0.43 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.42 |
| ▸ | ABAT | P80404 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14653580 | 0.82 | PDE2A (0.47) | CYP2A6ALDH1A1TYRCYP2A13HSD17B10 | |
| SCHEMBL31433123 | 0.80 | CYP2A6 (0.52) | CYP2A6ALDH1A1TYRCYP2A13HSD17B10 | |
| SCHEMBL6854404 | 0.80 | CYP2A6 (0.52) | CYP2A6ALDH1A1TYRCYP2A13HSD17B10 | |
| SCHEMBL4946530 | 0.80 | CYP2A6 (0.52) | CYP2A6ALDH1A1TYRCYP2A13HSD17B10 | |
| SCHEMBL61631 | 0.80 | CYP1A2 (0.54) | CYP2A6ALDH1A1HSD17B10ALDH5A1ABAT | |
| SCHEMBL6852179 | 0.80 | CYP2A6 (0.46) | CYP2A6ALDH1A1TYRCYP2A13HSD17B10 | |
| SCHEMBL31433071 | 0.80 | CYP2A6 (0.52) | CYP2A6ALDH1A1TYRCYP2A13HSD17B10 | |
| SCHEMBL43060 | 0.80 | EPHX2 (0.56) | CYP2A6ALDH1A1TYRCYP2A13HSD17B10 | |
| SCHEMBL12299036 | 0.79 | TSHR (0.40) | ALDH1A1TYRHSD17B10KIF11 | |
| SCHEMBL13675477 | 0.79 | HSD11B1 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107311846-B | Gem difluoroethyl substituted stilbene and diphenylethane derivatives, and preparation method and application thereof | 上海华理生物医药股份有限公司 | 2022-05-13 | — | — | CN | claimed |
| CN-107311846-A | Gem difluoroethyl substituted stilbene and diphenylethane derivatives, and preparation method and application thereof | 上海应用技术大学 | 2017-11-03 | — | — | CN | claimed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-107311846-B | Gem difluoroethyl substituted stilbene and diphenylethane derivatives, and preparation method and application thereof | 上海华理生物医药股份有限公司 | 2022-05-13 | — | — | CN | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| WO-2020035556-A1 | NOVEL HETEROAROMATIC MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA | LEO PHARMA A/S (DK) | 2020-02-20 | — | — | WO | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| WO-2019020029-A1 | GEM-DIFLUOROETHYL SUBSTITUTED STILBENE AND DIPHENYLETHANE DERIVATIVES, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海华理生物医药股份有限公司 | 2019-01-31 | — | — | WO | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| EP-2881384-B1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAISHO PHARMACEUTICAL CO LTD (JP) | 2018-05-30 | — | — | EP | disclosed |
| EP-2881384-B1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAISHO PHARMACEUTICAL CO LTD (JP) | 2018-05-30 | — | — | EP | disclosed |
| WO-2011004017-A1 | 1-(6 MEMBERS AZO-HETEROCYCLIC)-PYRROLIN-2-ONE COMPOUNDS AS INHIBITORS OF HEPATITIS C NS5B POLYMERASE, THE PHARMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE | VIVALIS (FR) | 2011-01-13 | — | — | WO | disclosed |
| EP-2215077-A1 | AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS | Prosidion Limited (GB) | 2010-08-11 | — | — | EP | disclosed |
| WO-2010083246-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2010-07-22 | — | — | WO | disclosed |
| WO-2010083246-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2010-07-22 | — | — | WO | disclosed |
| WO-2010081145-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GLAXOSMITHKLINE LLC (US) | 2010-07-15 | — | — | WO | disclosed |
| EP-1789402-B1 | 2-{-3-2-(PHENYL)-OXAZOL-4-YLMETHOXYMETHYL!-CYCLOHEXYLMETHOXY };-PROPIONIC ACID DERIVATIVES USED AS PPAR LIGANDES (PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS) FOR THE TREATMENT OF HYPERLIPIDAEMIE AND DIABETES | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-11-18 | — | — | EP | disclosed |
| US-20090197880-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. | 2009-08-06 | — | — | US | disclosed |
| WO-2009050522-A1 | AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS | PROSIDION LIMITED (GB) | 2009-04-23 | — | — | WO | disclosed |
| US-4173706-A | REACTING WITH MOLYBDENUM HEXAFLUORIDE | INSTITUTE NATIONAL DE RECHERCHE CHIMIQUE APPLIQUEE (FR) | 1979-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197880-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | HAVCR2, SARS1, RPL35 | CYP2A6 916/4885ALDH1A1 2251/4885TYR 1182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.